Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4⁺ T cells through regulating type 2 conventional dendritic cells.

ABSTRACT: Rationale: An immunosuppressive tumor microenvironment (TME) is a major obstacle in tumor immunotherapy. Stimulator of interferon genes (STING) agonists trigger an inflammatory innate immune response to potentially overcome tumor immunosuppression. While STING agonists may hold promise as potential cancer therapy agents, tumor resistance to STING monotherapy has emerged in clinical trials, and the mechanisms remain unclear. Methods: The in vivo anti-tumor immunity of STING agonist ADU-S100 (S100), plus anti-T cell immunoglobulin and mucin-domain containing-3 antibody (αTim-3) were measured using murine tumor models. Tumor-specific T cell activation and alterations in the TME were detected using flow cytometry. The maturation and function of dendritic cells (DC) were al

SUBMITTER: Luo J 

PROVIDER: S-EPMC10526657 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature